Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Baricitinib is known to reduce mortality and disease progression in COVID-19 patients; however, the data are inconsistent. Therefore, it needs to be explored to further understand the clinical benefits of this drug in the management of COVID-19 patients. Does baricitinib statistically significantly...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2022/8332819 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565644741050368 |
|---|---|
| author | Sivananthan Manoharan Lee Ying Ying |
| author_facet | Sivananthan Manoharan Lee Ying Ying |
| author_sort | Sivananthan Manoharan |
| collection | DOAJ |
| description | Baricitinib is known to reduce mortality and disease progression in COVID-19 patients; however, the data are inconsistent. Therefore, it needs to be explored to further understand the clinical benefits of this drug in the management of COVID-19 patients. Does baricitinib statistically significantly reduce mortality and disease progression in COVID-19 patients? To answer these questions, three databases known as ScienceDirect, PubMed/MEDLINE, and Scopus and other sources, such as preprint (medRxiv) and reference lists, were thoroughly searched. Four randomised controlled trials (RCTs) were included. Based on the meta-analysis, baricitinib statistically significantly reduced mortality with the risk ratio (RR) of RR = 0.74 [95% CI: 0.58 to 0.94; p=0.01] and moderately high heterogeneity, where I2 = 62% and p=0.05. On the other hand, RR = 0.84 [95% CI: 0.75 to 0.95; p=0.005] with insignificant heterogeneity of I2 = 20% and p=0.28 was found for disease progression. Cochrane risk of bias (RoB) analysis revealed that three out of four articles were ranked as high-quality articles with low RoB. Based on the evidence grading, the overall certainty of evidences was moderate. In conclusion, baricitinib statistically significantly reduced mortality and disease progression in COVID-19 patients when the patients were treated with baricitinib at a dosage of 2 mg or 4 mg for a maximum duration of 14 days. |
| format | Article |
| id | doaj-art-4a6e38c3f61b453594e61911e24aee40 |
| institution | Kabale University |
| issn | 1918-1493 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases and Medical Microbiology |
| spelling | doaj-art-4a6e38c3f61b453594e61911e24aee402025-02-03T01:06:58ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1918-14932022-01-01202210.1155/2022/8332819Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled TrialsSivananthan Manoharan0Lee Ying Ying1Molecular Pathology UnitAsia Metropolitan UniversityBaricitinib is known to reduce mortality and disease progression in COVID-19 patients; however, the data are inconsistent. Therefore, it needs to be explored to further understand the clinical benefits of this drug in the management of COVID-19 patients. Does baricitinib statistically significantly reduce mortality and disease progression in COVID-19 patients? To answer these questions, three databases known as ScienceDirect, PubMed/MEDLINE, and Scopus and other sources, such as preprint (medRxiv) and reference lists, were thoroughly searched. Four randomised controlled trials (RCTs) were included. Based on the meta-analysis, baricitinib statistically significantly reduced mortality with the risk ratio (RR) of RR = 0.74 [95% CI: 0.58 to 0.94; p=0.01] and moderately high heterogeneity, where I2 = 62% and p=0.05. On the other hand, RR = 0.84 [95% CI: 0.75 to 0.95; p=0.005] with insignificant heterogeneity of I2 = 20% and p=0.28 was found for disease progression. Cochrane risk of bias (RoB) analysis revealed that three out of four articles were ranked as high-quality articles with low RoB. Based on the evidence grading, the overall certainty of evidences was moderate. In conclusion, baricitinib statistically significantly reduced mortality and disease progression in COVID-19 patients when the patients were treated with baricitinib at a dosage of 2 mg or 4 mg for a maximum duration of 14 days.http://dx.doi.org/10.1155/2022/8332819 |
| spellingShingle | Sivananthan Manoharan Lee Ying Ying Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials Canadian Journal of Infectious Diseases and Medical Microbiology |
| title | Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials |
| title_full | Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials |
| title_fullStr | Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials |
| title_full_unstemmed | Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials |
| title_short | Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials |
| title_sort | baricitinib for the management of sars cov 2 infected patients a systematic review and meta analysis of randomised controlled trials |
| url | http://dx.doi.org/10.1155/2022/8332819 |
| work_keys_str_mv | AT sivananthanmanoharan baricitinibforthemanagementofsarscov2infectedpatientsasystematicreviewandmetaanalysisofrandomisedcontrolledtrials AT leeyingying baricitinibforthemanagementofsarscov2infectedpatientsasystematicreviewandmetaanalysisofrandomisedcontrolledtrials |